MedTrace Logo

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

NCT01952574 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 483

Last updated 2022-10-12

Study results available
· View outcomes & findings →

Summary

A study to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days in participants with episodic migraine.

Conditions

Interventions

DRUG

Erenumab

Administered by study site staff once a month (QM) as a subcutaneous injection

DRUG

Placebo

Administered by study site staff once a month (QM) as a subcutaneous injection

DRUG

Erenumab PFS

Erenumab supplied in a single-use prefilled syringe for self-administration in the CHU substudy

DRUG

Erenumab AI/Pen

Erenumab supplied in a single-use autoinjector/pen for self-administration in the CHU substudy

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-06
Primary Completion
2014-09-25
Completion
2019-11-12

Countries

  • United States
  • Canada
  • Denmark
  • Finland
  • Germany
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01952574 on ClinicalTrials.gov